Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 23084849)

1.

The economic value of a quadrivalent versus trivalent influenza vaccine.

Lee BY, Bartsch SM, Willig AM.

Vaccine. 2012 Dec 14;30(52):7443-6. doi: 10.1016/j.vaccine.2012.10.025. Epub 2012 Oct 19. Erratum in: Vaccine. 2013 May 7;31(20):2477-9.

2.

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.

Beran J, Peeters M, Dewé W, Raupachová J, Hobzová L, Devaster JM.

BMC Infect Dis. 2013 May 20;13:224. doi: 10.1186/1471-2334-13-224.

3.

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.

Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.

BMC Infect Dis. 2013 Jul 24;13:343. doi: 10.1186/1471-2334-13-343.

4.

A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.

Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.

J Infect Dis. 2013 Jun 15;207(12):1878-87. doi: 10.1093/infdis/jit091. Epub 2013 Mar 7.

5.

4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany.

Eichner M, Schwehm M, Hain J, Uphoff H, Salzberger B, Knuf M, Schmidt-Ott R.

BMC Infect Dis. 2014 Jul 3;14:365. doi: 10.1186/1471-2334-14-365.

6.

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.

Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M.

Vaccine. 2013 Nov 12;31(47):5572-8. doi: 10.1016/j.vaccine.2013.08.069. Epub 2013 Sep 7.

PMID:
24016810
7.

Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.

Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK.

Vaccine. 2014 Mar 14;32(13):1480-7. doi: 10.1016/j.vaccine.2014.01.022. Epub 2014 Jan 28.

8.

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.

Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD.

Vaccine. 2013 Jan 21;31(5):770-6. doi: 10.1016/j.vaccine.2012.11.074. Epub 2012 Dec 8.

PMID:
23228813
9.

A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine.

Jain VK, Chandrasekaran V, Wang L, Li P, Liu A, Innis BL.

BMC Infect Dis. 2014 Mar 10;14:133. doi: 10.1186/1471-2334-14-133.

10.

Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.

Greenberg DP, Robertson CA, Landolfi VA, Bhaumik A, Senders SD, Decker MD.

Pediatr Infect Dis J. 2014 Jun;33(6):630-6. doi: 10.1097/INF.0000000000000254.

PMID:
24445833
11.

Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.

Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ.

Vaccine. 2008 Jun 2;26(23):2841-8. doi: 10.1016/j.vaccine.2008.03.046. Epub 2008 May 6.

PMID:
18462851
12.

Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine.

Reed C, Meltzer MI, Finelli L, Fiore A.

Vaccine. 2012 Mar 2;30(11):1993-8. doi: 10.1016/j.vaccine.2011.12.098. Epub 2012 Jan 5.

PMID:
22226861
13.

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children.

Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA, McNeil S, Reisinger KS, Aggarwal N, Huang LM, Peng CT, Garcia-Sicilia J, Salamanca de la Cueva I, Cabañas F, Treviño-Garza C, Rodríguez-Weber MA, de la O M, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK.

J Infect Dis. 2013 Aug 15;208(4):544-53. doi: 10.1093/infdis/jit263. Epub 2013 Jul 11. Erratum in: J Infect Dis. 2014 May 1;209(9):1494.

15.

Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong.

You JH, Ming WK, Chan PK.

BMC Infect Dis. 2014 Nov 25;14:618. doi: 10.1186/s12879-014-0618-9.

16.

Economics of influenza vaccine administration timing for children.

Lee BY, Tai JH, Bailey RR, Smith KJ, Nowalk AJ.

Am J Manag Care. 2010 Mar;16(3):e75-e85.

17.

Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.

You JH, Ming WK, Chan PK.

Hum Vaccin Immunother. 2015;11(3):564-71. doi: 10.1080/21645515.2015.1011016.

PMID:
25714506
18.

Health and economic impact of the seasonal influenza vaccination programme in England.

Baguelin M, Jit M, Miller E, Edmunds WJ.

Vaccine. 2012 May 14;30(23):3459-62. doi: 10.1016/j.vaccine.2012.03.019. Epub 2012 Mar 22.

PMID:
22446636
19.

Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.

Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, Gubbay JB, Dickinson JA, Fonseca K, Charest H, Bastien N, Li Y, Kwindt TL, Mahmud SM, Van Caeseele P, Krajden M, Petric M.

J Infect Dis. 2014 Jul 1;210(1):126-37. Epub 2014 Jan 19.

20.

Public health and economic benefits of new pediatric influenza vaccination programs in Argentina.

Giglio N, Gentile A, Lees L, Micone P, Armoni J, Reygrobellet C, Crépey P.

Hum Vaccin Immunother. 2012 Mar;8(3):312-22. doi: 10.4161/hv.18569. Epub 2012 Feb 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk